PODCAST: Gut check

Food Insecurity and the Dangers of Infant Formula Dilution

Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH.

January 30th 2023

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

Demystifying Infant Formula

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

October 11th 2022

Addictive behaviors surrounding social media could lead to binge eating

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.

Investigating mono vs dual therapy for pediatric pulmonary arterial hypertension

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH.

January 30th 2023

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

Demystifying Infant Formula

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

October 11th 2022

Addictive behaviors surrounding social media could lead to binge eating

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.